Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults
Published: Apr 08, 2021 Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe AJOVY® is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults. AJOVY® is supported by the AJOVY® Teva Support Solutions® (AJOVY® TSS) Patient Support Program, whose...
Source: biospace.com